ijms-logo

Journal Browser

Journal Browser

Vaccination against Enterobacteriaceae: From Pre-clinical Models to Translation

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Microbiology".

Deadline for manuscript submissions: 20 September 2024 | Viewed by 1247

Special Issue Editor


E-Mail Website
Guest Editor
Medical Immunology Campus Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany
Interests: mucosal immunology; inflammatory bowel disease; lipid biology; cytokines; microbiota; gastrointestinal infections; allelic variations; genetic susceptibility; vaccination
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Some members of the family of Enterobacteriaceae are part of the physiological gut microbiota or transiently colonize the intestine without causing any harm. However, Enterobacteriaceae can also cause severe and even life-threatening infections of multiple organ systems following the acquisition of virulence plasmids or the disruption of commensal microbiota (dysbiosis). Due to the increasing frequency of infections with Enterobacteriaceae in clinical settings and the outbreaks of multi-resistant strains, the use of antibiotics for treatment is increasingly limited. To prevent the spread of multi-drug-resistant Enterobacteriaceae, vaccination next to antibiotic stewardship programs is an alternative promising option. Depending on the species-specific infection sites, the presentation of antigens and the route of immunization need to be carefully considered. Furthermore, the unavailability of suitable animal models for some Enterobacteriaceae hampers preclinical testing and the subsequent design of clinical trials. Thus, novel avenues need to be pursued to characterize the nature of bacterial antigens and to obtain effective vaccine candidates.

Since IJMS is a journal of molecular science, pure clinical studies are not suitable. However, we welcome clinical submissions with biomolecular experiments and encourage authors to reveal new molecular mechanisms in their research.

Prof. Dr. Jochen Mattner
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • enterobacteriaceae
  • (mucosal) vaccines
  • immunity
  • intestinal microbiota
  • dysbiosis
  • microbial pathogenesis
  • animal models

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

25 pages, 2078 KiB  
Review
Shigella Vaccines: The Continuing Unmet Challenge
by Ti Lu, Sayan Das, Debaki R. Howlader, William D. Picking and Wendy L. Picking
Int. J. Mol. Sci. 2024, 25(8), 4329; https://doi.org/10.3390/ijms25084329 - 13 Apr 2024
Viewed by 1000
Abstract
Shigellosis is a severe gastrointestinal disease that annually affects approximately 270 million individuals globally. It has particularly high morbidity and mortality in low-income regions; however, it is not confined to these regions and occurs in high-income nations when conditions allow. The ill effects [...] Read more.
Shigellosis is a severe gastrointestinal disease that annually affects approximately 270 million individuals globally. It has particularly high morbidity and mortality in low-income regions; however, it is not confined to these regions and occurs in high-income nations when conditions allow. The ill effects of shigellosis are at their highest in children ages 2 to 5, with survivors often exhibiting impaired growth due to infection-induced malnutrition. The escalating threat of antibiotic resistance further amplifies shigellosis as a serious public health concern. This review explores Shigella pathology, with a primary focus on the status of Shigella vaccine candidates. These candidates include killed whole-cells, live attenuated organisms, LPS-based, and subunit vaccines. The strengths and weaknesses of each vaccination strategy are considered. The discussion includes potential Shigella immunogens, such as LPS, conserved T3SS proteins, outer membrane proteins, diverse animal models used in Shigella vaccine research, and innovative vaccine development approaches. Additionally, this review addresses ongoing challenges that necessitate action toward advancing effective Shigella prevention and control measures. Full article
Show Figures

Figure 1

Back to TopTop